S&P 500   3,982.78 (+0.79%)
DOW   32,416.86 (+0.53%)
QQQ   307.85 (+0.61%)
AAPL   158.21 (+0.51%)
MSFT   271.92 (-0.11%)
META   200.66 (+1.44%)
GOOGL   104.38 (+3.12%)
AMZN   99.33 (+1.66%)
TSLA   195.29 (+6.57%)
NVDA   258.25 (-0.29%)
NIO   9.22 (+5.37%)
BABA   83.28 (+2.81%)
AMD   94.77 (-2.11%)
T   18.47 (-0.11%)
F   11.73 (+4.92%)
MU   58.10 (+0.80%)
CGC   1.97 (+5.91%)
GE   92.63 (+3.01%)
DIS   96.18 (+2.08%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.56 (+3.21%)
NFLX   305.63 (+0.16%)
S&P 500   3,982.78 (+0.79%)
DOW   32,416.86 (+0.53%)
QQQ   307.85 (+0.61%)
AAPL   158.21 (+0.51%)
MSFT   271.92 (-0.11%)
META   200.66 (+1.44%)
GOOGL   104.38 (+3.12%)
AMZN   99.33 (+1.66%)
TSLA   195.29 (+6.57%)
NVDA   258.25 (-0.29%)
NIO   9.22 (+5.37%)
BABA   83.28 (+2.81%)
AMD   94.77 (-2.11%)
T   18.47 (-0.11%)
F   11.73 (+4.92%)
MU   58.10 (+0.80%)
CGC   1.97 (+5.91%)
GE   92.63 (+3.01%)
DIS   96.18 (+2.08%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.56 (+3.21%)
NFLX   305.63 (+0.16%)
S&P 500   3,982.78 (+0.79%)
DOW   32,416.86 (+0.53%)
QQQ   307.85 (+0.61%)
AAPL   158.21 (+0.51%)
MSFT   271.92 (-0.11%)
META   200.66 (+1.44%)
GOOGL   104.38 (+3.12%)
AMZN   99.33 (+1.66%)
TSLA   195.29 (+6.57%)
NVDA   258.25 (-0.29%)
NIO   9.22 (+5.37%)
BABA   83.28 (+2.81%)
AMD   94.77 (-2.11%)
T   18.47 (-0.11%)
F   11.73 (+4.92%)
MU   58.10 (+0.80%)
CGC   1.97 (+5.91%)
GE   92.63 (+3.01%)
DIS   96.18 (+2.08%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.56 (+3.21%)
NFLX   305.63 (+0.16%)
S&P 500   3,982.78 (+0.79%)
DOW   32,416.86 (+0.53%)
QQQ   307.85 (+0.61%)
AAPL   158.21 (+0.51%)
MSFT   271.92 (-0.11%)
META   200.66 (+1.44%)
GOOGL   104.38 (+3.12%)
AMZN   99.33 (+1.66%)
TSLA   195.29 (+6.57%)
NVDA   258.25 (-0.29%)
NIO   9.22 (+5.37%)
BABA   83.28 (+2.81%)
AMD   94.77 (-2.11%)
T   18.47 (-0.11%)
F   11.73 (+4.92%)
MU   58.10 (+0.80%)
CGC   1.97 (+5.91%)
GE   92.63 (+3.01%)
DIS   96.18 (+2.08%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.56 (+3.21%)
NFLX   305.63 (+0.16%)
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$319.00
+0.70 (+0.22%)
(As of 03/21/2023 01:03 PM ET)
Add
Compare
Today's Range
$317.10
$321.21
50-Day Range
$276.36
$318.30
52-Week Range
$181.00
$321.21
Volume
302,828 shs
Average Volume
860,860 shs
Market Capitalization
$22.18 billion
P/E Ratio
5,316.67
Dividend Yield
N/A
Price Target
$317.82

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
0.1% Downside
$317.82 Price Target
Short Interest
Healthy
3.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.51mentions of Insulet in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$13.65 M Sold Last Quarter
Proj. Earnings Growth
56.59%
From $1.29 to $2.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

464th out of 988 stocks

Surgical & Medical Instruments Industry

47th out of 101 stocks


PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Should You Invest in Insulet Corporation (PODD)?
This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
Company News for Mar 14, 2023
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Should You Hold Insulet Corporation (PODD)?
Insulet (PODD) Q4 Earnings and Revenues Beat Estimates
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
2/23/2023
Today
3/21/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,600
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$317.82
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$260.00
Forecasted Upside/Downside
-0.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Net Income
$4.60 million
Pretax Margin
0.75%

Debt

Sales & Book Value

Annual Sales
$1.31 billion
Cash Flow
$2.29 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
68,916,000
Market Cap
$22.13 billion
Optionable
Optionable
Beta
0.75

Social Links


Key Executives

  • James R. Hollingshead
    President, Chief Executive Officer & Director
  • Prem Singh
    Senior Vice President-Global Operations
  • Wayde Dwight McMillan
    Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly
    Senior Vice President & Medical Director
  • Michael P. Spears
    Senior VP-Quality, Regulatory Affairs & Compliance













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

11 Wall Street analysts have issued 1 year target prices for Insulet's shares. Their PODD share price forecasts range from $260.00 to $350.00. On average, they anticipate the company's share price to reach $317.82 in the next twelve months. This suggests that the stock has a possible downside of 0.2%.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD shares have increased by 8.1% and is now trading at $318.30.
View the best growth stocks for 2023 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its earnings results on Thursday, February, 23rd. The medical instruments supplier reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.31. The medical instruments supplier had revenue of $369.70 million for the quarter, compared to the consensus estimate of $331.73 million. Insulet had a net margin of 0.35% and a trailing twelve-month return on equity of 20.55%. The company's revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.42 earnings per share.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $327.89 million-$336.76 million, compared to the consensus revenue estimate of $333.86 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.45%), Clearbridge Investments LLC (2.30%), Moneta Group Investment Advisors LLC (1.87%), Geode Capital Management LLC (1.38%), Fred Alger Management LLC (0.81%) and Allspring Global Investments Holdings LLC (0.65%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $318.30.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $22.13 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,600 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 3/21/2023 by MarketBeat.com Staff